Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424699 | 0.81 | ALDH1A1 (0.52) | FDPSCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL1626212 | 0.81 | HPGD (0.49) | HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL1625904 | 0.80 | KDM4E (0.41) | KDM4EQPCTALDH1A1HRH4 | |
| SCHEMBL1628159 | 0.76 | MAOB (0.43) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1627975 | 0.75 | HRH4 (0.43) | QPCTHRH4 | |
| SCHEMBL5451545 | 0.74 | HPGD (0.54) | HPGDFDPSALDH1A1ALDH1A3 | |
| SCHEMBL5440983 | 0.74 | FDPS (0.54) | HPGDFDPSKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5692621 | 0.73 | POLB (0.56) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5451218 | 0.73 | HPGD (0.59) | HPGDFDPSALDH1A1ALDH1A3 | |
| SCHEMBL5449465 | 0.73 | FDPS (0.53) | HPGDFDPSALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723526-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723527-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7723359-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-25 | — | — | US | disclosed |
| US-7705149-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705143-B2 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-[1,4]diazepan-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions | JANSSEN PHARMACEUTICA N.V. (BG) | 2010-04-27 | — | — | US | disclosed |
| US-7662966-B2 | For example, 5-tert-Butyl-2-{2-[4-(1-methyl-piperidin-4-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; use in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-16 | — | — | US | disclosed |
| US-20090281307-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-12 | — | — | US | disclosed |
| US-20090275748-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-05 | — | — | US | disclosed |
| US-20090270611-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270613-A1 | Benzoimidazole compounds | EDWARDS JAMES P | 2009-10-29 | — | — | US | disclosed |
| US-20090270366-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090264645-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264646-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090247508-A1 | Benzoimidazole Compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-01 | — | — | US | disclosed |
| EP-1673348-B1 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| US-7432378-B2 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-07 | — | — | US | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270613-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090264646-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090270366-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090270611-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090275748-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090264647-A1 | 5-Fluoro-4-methyl-2-{2-[4-(4-methyl-piperazin-1-yl)-butoxy]-pyridin-4-yl}-1H-benzoimidazole; leukocyte recruitment inhibition, modulating H4 receptor, and treating conditions such as inflammation | HRH4, HRH3, BRD4 | HPGD 1686/4885FDPS 3118/4885CYP1A2 3438/4885 |
| US-20090247508-A1 | Benzoimidazole Compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090264645-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
| US-20090281307-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | HPGD 2022/4885FDPS 4018/4885CYP1A2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.